Spectral Medical Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•06/11/2026•07:00 ET
0
Key Highlights
- ➤C$14.0 million convertible-note financing targets PMX regulatory work and working capital
- ➤FDA deficiency letter requests clarification, additional analyses and testing; no additional clinical trial requested
- ➤Q3 revenue $275,000, down 59% year over year
- ➤Q3 net income $5.099 million, versus $30.316 million loss previously
- ➤Financing expected to fund operations through anticipated FDA PMA decision
Expert Statements
Chris Seto, Chief Executive Officer of Spectral Medical
“The recent financing is expected to provide the funding needed to advance PMX through the anticipated FDA PMA decision”
Chris Seto, Chief Executive Officer of Spectral Medical
“With this funding in place, we can focus on addressing the FDA’s feedback, supporting ongoing review and inspection activities, and preparing for potential commercialization with Vantive and Toray.”
John A. Kellum, Chief Medical Officer of Spectral Medical
“The Tigris clinical evidence, including follow-up through one year, remains central to our PMA application.”
John A. Kellum, Chief Medical Officer of Spectral Medical
“Our team is focused on addressing the FDA’s analytical and testing requests and supporting its assessment of the totality of evidence for PMX in patients with endotoxic septic shock.”
• Recent financing expected to fund operations through anticipated FDA PMA decision
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2026 and provided a corporate update.
Get started
Create a free account to read the full story.